Stock Market News
SkinBio Therapeutics agrees collaboration with University of Manchester
Life sciences company SkinBio Therapeutics will assist the University of Manchester with its investigation into how ageing affects the skin, in return for first refusal on any intellectual property that emerges.
SkinBio's collaboration with the university follows a £600,000 grant awarded to the school by the Biotechnology & Biological Sciences Research Council to enable it to carry out research which could lead to the development of novel ways to improve the health of the skin microbiome during ageing and in turn, support new approaches to prevent age-related skin conditions and promote long-term skin health.
The AIM-quoted company will act as an industrial partner on the project and will have the first refusal on any IP generated by the project, placing the company in a strong position to develop any relevant findings with the potential to extend its current portfolio of indications in skin health, anti-infection and repair.
Dr Catherine O'Neill, chief executive of SkinBioTherapeutics, said, "Unlike the gut, virtually nothing is known about possible prebiotics for the skin. This study will provide the foundations for developing novel prebiotic treatments for aged skin. This work is very complementary to the work that we have already underway at SkinBioTherapeutics in skin care, anti-infection and repair."
As of 1100 BST, SkinBio shares had collected 8.24% to 15.60p.
SkinBio's collaboration with the university follows a £600,000 grant awarded to the school by the Biotechnology & Biological Sciences Research Council to enable it to carry out research which could lead to the development of novel ways to improve the health of the skin microbiome during ageing and in turn, support new approaches to prevent age-related skin conditions and promote long-term skin health.
The AIM-quoted company will act as an industrial partner on the project and will have the first refusal on any IP generated by the project, placing the company in a strong position to develop any relevant findings with the potential to extend its current portfolio of indications in skin health, anti-infection and repair.
Dr Catherine O'Neill, chief executive of SkinBioTherapeutics, said, "Unlike the gut, virtually nothing is known about possible prebiotics for the skin. This study will provide the foundations for developing novel prebiotic treatments for aged skin. This work is very complementary to the work that we have already underway at SkinBioTherapeutics in skin care, anti-infection and repair."
As of 1100 BST, SkinBio shares had collected 8.24% to 15.60p.
Related share prices |
---|
SkinBioTherapeutics (SBTX) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price